BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211022T093000
DTEND;TZID=America/New_York:20211022T103000
DTSTAMP:20260423T133151
CREATED:20210819T182315Z
LAST-MODIFIED:20211001T204352Z
UID:5556-1634895000-1634898600@carb-x.org
SUMMARY:CARB-X WEBINAR: European Celebration of 5 Years of Progress with CARB-X
DESCRIPTION:European Celebration of 5 Years of Progress with CARB-X \nA virtual discussion of progress and plans to accelerate innovation globally \n22nd of October\, 2021\, 3:30 – 4:30pm CET / 9:30 – 10:30am ET  \nAntibiotic-resistance undermines the safety net for modern medicine. Chemotherapy\, surgeries\, transplantation\, childbirth – all of these and more depend on antibiotics to treat infection.  At least 700\,000 people die each year due to antibiotic-resistant (AMR) infections\, according to a recent WHO report. A recent Lancet publication from the European Center for Disease Prevention and Control (ECDC) estimates that approximately 33\,000 deaths in the EU each year can be attributed to AMR\, and an Organization of Economic Cooperation & Development OECD report calculates about 1.1 billion Euros are required for the health care systems of EU/EEA countries to address AMR. \nCARB-X and its partners are taking action. CARB-X has funded 92 projects in 12 countries totaling more than $360 million since it launched in 2016. In Europe\, the support of Wellcome Trust\, the German Ministry of Health and Education\, and the UK Global AMR Innovation Fund was critical to this progress over the past five years. \nToday\, the CARB-X portfolio is the world’s largest and most scientifically diverse antibacterial R&D portfolio. We are currently accelerating projects focused on the most serious antibiotic-resistant bacteria\, including new classes of antibiotics and non-traditional agents\, vaccines and other preventatives such as CRISPR-phage\, microbiome-modifying agents and antibodies\, and rapid diagnostics. \nPlease join us for a virtual discussion of the critical role that CARB-X and its global partners play in driving the development of innovative products to address the antibiotic-resistant bacteria health crisis. \nCARB-X Executive Director Kevin Outterson will highlight achievements\, especially in Europe and speak to CARB-X’s future vision and strategy. \nEuropean-based funders of CARB-X will outline their objectives and strategy in preparedness and how CARB-X delivery over 2016-2021 has met some of these goals. \nSeveral European product developers in the current CARB-X portfolio will speak about their innovative products and their experience working with CARB-X. \nA panel of experts will discuss antibiotics as the safety net for modern medicine and the challenges of bringing innovative products to patients in Europe. \n\nVeronika von Messling – Director-General for Life Sciences at the German Federal Ministry of Education and Research (confirmed)\nFlorence Séjourné – Chief Executive Director of Da Volterra and President of BEAM Alliance (confirmed)\nSir Jeremy Farrar – Director of Wellcome Trust & Member of the One Health Global Leaders Group on AMR (confirmed)\n Otto Cars – Founding Director of ReAct\, Senior Professor\, Infectious Diseases\, Uppsala University\, and former member of UN Inter-Agency Coordination Group on AMR (confirmed)\n\nClick here to register\, and to find out more about this important virtual meeting.
URL:https://carb-x.org/event/carb-x-webinar-european-celebration-of-5-years-of-progress-with-carb-x/
LOCATION:WEBINAR\, Webinar\, Webinar\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20210720T163000
DTEND;TZID=Europe/London:20210720T180000
DTSTAMP:20260423T133151
CREATED:20210623T174658Z
LAST-MODIFIED:20210623T174741Z
UID:5478-1626798600-1626804000@carb-x.org
SUMMARY:BSAC and LP Webinar: Diagnostic driven strategies for antimicrobial resistance in the UK
DESCRIPTION:BSAC Infection Clinical Dilema Series\nWebinar: Diagnostic driven strategies for antimicrobial resistance in the UK\n\nLongitude Prize is partnering with British Society for Antimicrobial Chemotherapy (BSAC) for the Infection Clinical Dilemmas webinar series. It will bring diagnostic developers together with clinicians and professional bodies working on diagnostic evaluation in and for the National Health Service (NHS) in the UK\, to build an understanding of the NHS commissioning path for AMR diagnostic tests. The event will include presentations by the Head of AMR at NHS England and National Institute for Health and Care Excellence (NICE)\, followed by an interactive ‘Ask an Expert’ session – with experts from Medicines and Healthcare products Regulatory Agency (MHRA)\, University of Oxford NIHR Community Healthcare MedTech and IVD Cooperative and clinicians – for developers to express challenges they face and ask questions about marketing access in the UK.\n\n\nThe webinar will take place on Tuesday 20th July\, 1630-1800hrs BST \nClick here to sign-up and register.
URL:https://carb-x.org/event/bsac-and-lp-webinar-diagnostic-driven-strategies-for-antimicrobial-resistance-in-the-uk/
LOCATION:WEBINAR\, Webinar\, Webinar\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210512T110000
DTEND;TZID=America/New_York:20210512T123000
DTSTAMP:20260423T133151
CREATED:20210510T191153Z
LAST-MODIFIED:20210510T191338Z
UID:5336-1620817200-1620822600@carb-x.org
SUMMARY:Duke-Margolis Center for Health Policy Webinar: Combating Rising Antimicrobial Resistance (AMR) & Advancing Public Health Preparedness
DESCRIPTION:Join the Duke-Margolis Center for Health Policy—including an introduction by former FDA Commissioners Dr. Mark McClellan and Dr. Scott Gottlieb—for an important discussion on combating rising antimicrobial resistance (AMR) in the context of U.S. public health preparedness\, support for novel antibiotics\, global AMR policy leadership\, and emerging multi-sector innovation. \nRising antimicrobial resistance remains a top global public health threat and efforts to support novel antibiotic development and availability are more critical and timely than ever. As the ongoing pandemic centers national and global conversations around actions to prevent and combat future infectious disease threats\, the time to take action against AMR is now. \nCARB-X participants include Kevin Outterson\, Executive Director\, who will join the panel for Session 2: Global Policy Leadership and Proposals to Combat AMR at 11:25AM ET.  This session will highlight how the U.S. can lead policy approaches to combat AMR through existing legislative proposals and opportunities to coordinate domestic\nactions with existing international efforts.  \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/duke-margolis-center-for-health-policy-webinar-combating-rising-antimicrobial-resistance-amr-advancing-public-health-preparedness/
LOCATION:WEBINAR\, Webinar\, Webinar\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210114T110000
DTEND;TZID=America/New_York:20210114T123000
DTSTAMP:20260423T133151
CREATED:20201215T155536Z
LAST-MODIFIED:20201215T155536Z
UID:4822-1610622000-1610627400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Manipulating the host response to treat infections
DESCRIPTION:Immune modulation and host directed therapies as an adjunctive approach to treating infections (R.E.W. (Bob) Hancock):  \n\nHost defence peptides (HDP; often termed antimicrobial peptides) stimulate protective immunity while suppressing potentially harmful inflammation. Both of these activities can assist in anti-infective therapy.\nHDPs work as immune modulators in animal models against ESKAPE pathogen\, MDR TB\, fungal\, malaria and viral infections\, as well as sterile inflammation. They are likely to be employed in adjunctive therapy in combination with antibiotics.\nHDPs often have additional value-added activities including action against bacterial biofilms in animal models. This allows them to be utilized to address situations where antibiotics commonly fail.\nAlternative host-directed therapies can be defined for recalcitrant infections using stem cell mutagenesis and systems biology approaches.\n\nRegulation and reprogramming of the innate immune system as alternative to antibiotics (Henk P. Haagsman):  \n\nHost defence peptides (HDP) are immunomodulatory antimicrobials. – Cathelicidin-derived peptides may serve as paradigms to develop anti-inflammatory anti-infectives.\nCathelicidin-derived peptides may be used prophylactically as immunomodulators and adjuvants in veterinary medicine.\nHost-directed therapy may include innate immune training by epigenetic reprogramming. The presentations will be followed by a Q&A session.\n\nSpeakers: R.E.W. (Bob) Hancock\, University of British Columbia (Canada); Henk P. Haagsman\, Utrecht University (Netherlands) \nModerator: Neeloffer Mookherjee\, Departments of Internal Medicine and Immunology\, University of Manitoba (Canada) \nClick here to learn more and register.
URL:https://carb-x.org/event/live-webinar-gardp-revive-manipulating-the-host-response-to-treat-infections/
LOCATION:WEBINAR\, Webinar\, Webinar\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190129T110000
DTEND;TZID=America/New_York:20190129T123000
DTSTAMP:20260423T133151
CREATED:20181210T194947Z
LAST-MODIFIED:20190124T152941Z
UID:2050-1548759600-1548765000@carb-x.org
SUMMARY:REVIVE Webinar: Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products
DESCRIPTION:On the 29th of January 2019\, Ian Friedland\, Sumathi Nambiar\, Mair Powell\, and David Shlaes will join us for a live webinar about antibacterial drug enhancer combinations and non-traditional products. Following their short presentations\, the speakers will be available on the line to respond to your questions.
URL:https://carb-x.org/event/revive-webinar-clinical-development-for-non-developers-part-3-antibacterial-drug-enhancer-combinations-and-non-traditional-products/
LOCATION:WEBINAR\, Webinar\, Webinar\, United States
END:VEVENT
END:VCALENDAR